Insertable Cardiac Monitor for Primary Atrial Fibrillation Detection in High-Risk Heart Failure Patients

NARecruitingINTERVENTIONAL
Enrollment

477

Participants

Timeline

Start Date

January 31, 2023

Primary Completion Date

July 1, 2028

Study Completion Date

July 1, 2028

Conditions
Atrial FibrillationHeart Failure
Interventions
DEVICE

ASSERT Insertable Cardiac Monitor

Subjects will be subcutaneously implanted with an Abbott ASSERT ICM with the device implant procedure per standard of care and current labelling. Data related to subjects' arrhythmias, via the Merlin.net Patient CareNetwork will be transmitted on a monthly basis to the treating physician and subsequently to the study coordination and database center (CCRC) at the University of Rochester. Data on the frequency/types of symptomatic (patient triggered) versus ICM detected (asymptomatic) arrhythmic events will be collected and adjudicated. Clinical data on medication, device interventions, cardiovascular events will be collected at follow-up visits.

OTHER

Conventional Management and monitoring

Subjects randomized to the conventional management arm of the trial will undergo arrhythmia monitoring based on clinical indications and per standard available modalities including periodic electrocardiograms (ECG), Holter and/or event monitoring.

Trial Locations (1)

14642

RECRUITING

University of Rochester Medical Center, Rochester

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Abbott

INDUSTRY

lead

University of Rochester

OTHER

NCT04818645 - Insertable Cardiac Monitor for Primary Atrial Fibrillation Detection in High-Risk Heart Failure Patients | Biotech Hunter | Biotech Hunter